Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073640729> ?p ?o ?g. }
- W2073640729 endingPage "481" @default.
- W2073640729 startingPage "477" @default.
- W2073640729 abstract "As both fludarabine and rituximab are active against indolent lymphoproliferative disorders, we have studied the combination of fludarabine and rituximab in patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) in phase I/II fashion. Of 33 patients enrolled, 21(63.6%) had low-grade lymphoma and 12 (36.4%) had CLL. They received fludarabine 30 mg/m2 on days 1-4 and rituximab 125, 250 or 375 mg/m2 on day 5 at intervals of 28 days to a maximum of 8 cycles. Three patients were removed from the study because of rituximab-associated anaphylaxis and four because of prolonged hematopoietic toxicity. Toxicity and responsiveness did not differ at the different dose levels of rituximab. For 29 evaluable patients, responses were seen in 82.8% and complete responses in 34.5%. Of 7 responding patients not referred for stem cell transplantation, 6 remain in complete remission at a median follow-up of 16 months (range 4-30 months). Of 13 previously untreated patients, all responded and 46.2% had a complete response. Of 16 previously treated patients, 68.5% responded and 25% had a complete response. The combination of fludarabine and rituximab has major activity and acceptable toxicity in patients with low-grade lymphoma and CLL." @default.
- W2073640729 created "2016-06-24" @default.
- W2073640729 creator A5004951877 @default.
- W2073640729 creator A5005667345 @default.
- W2073640729 creator A5011005041 @default.
- W2073640729 creator A5020913460 @default.
- W2073640729 creator A5022780678 @default.
- W2073640729 creator A5026614969 @default.
- W2073640729 creator A5042096312 @default.
- W2073640729 creator A5050441373 @default.
- W2073640729 creator A5055051085 @default.
- W2073640729 creator A5057870068 @default.
- W2073640729 creator A5061331583 @default.
- W2073640729 creator A5062490222 @default.
- W2073640729 creator A5074661473 @default.
- W2073640729 creator A5078275347 @default.
- W2073640729 creator A5082193608 @default.
- W2073640729 date "2003-01-01" @default.
- W2073640729 modified "2023-10-16" @default.
- W2073640729 title "Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia" @default.
- W2073640729 cites W1685882185 @default.
- W2073640729 cites W1785340630 @default.
- W2073640729 cites W1848698181 @default.
- W2073640729 cites W1854920159 @default.
- W2073640729 cites W1868739127 @default.
- W2073640729 cites W1880801097 @default.
- W2073640729 cites W1881313440 @default.
- W2073640729 cites W1910831415 @default.
- W2073640729 cites W1912693401 @default.
- W2073640729 cites W1915689252 @default.
- W2073640729 cites W1939111644 @default.
- W2073640729 cites W1972073735 @default.
- W2073640729 cites W1979462386 @default.
- W2073640729 cites W1988881099 @default.
- W2073640729 cites W2032423298 @default.
- W2073640729 cites W2042483573 @default.
- W2073640729 cites W2066388140 @default.
- W2073640729 cites W206701898 @default.
- W2073640729 cites W2070193300 @default.
- W2073640729 cites W2104940816 @default.
- W2073640729 cites W2112476236 @default.
- W2073640729 cites W2116262245 @default.
- W2073640729 cites W2129041705 @default.
- W2073640729 cites W2161926682 @default.
- W2073640729 cites W2167635913 @default.
- W2073640729 cites W2264636885 @default.
- W2073640729 cites W2266889995 @default.
- W2073640729 cites W2326175431 @default.
- W2073640729 cites W2916663880 @default.
- W2073640729 cites W4230324843 @default.
- W2073640729 cites W4242167328 @default.
- W2073640729 cites W60865865 @default.
- W2073640729 cites W96780237 @default.
- W2073640729 doi "https://doi.org/10.1080/1042819021000046958" @default.
- W2073640729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12688318" @default.
- W2073640729 hasPublicationYear "2003" @default.
- W2073640729 type Work @default.
- W2073640729 sameAs 2073640729 @default.
- W2073640729 citedByCount "30" @default.
- W2073640729 countsByYear W20736407292014 @default.
- W2073640729 countsByYear W20736407292019 @default.
- W2073640729 crossrefType "journal-article" @default.
- W2073640729 hasAuthorship W2073640729A5004951877 @default.
- W2073640729 hasAuthorship W2073640729A5005667345 @default.
- W2073640729 hasAuthorship W2073640729A5011005041 @default.
- W2073640729 hasAuthorship W2073640729A5020913460 @default.
- W2073640729 hasAuthorship W2073640729A5022780678 @default.
- W2073640729 hasAuthorship W2073640729A5026614969 @default.
- W2073640729 hasAuthorship W2073640729A5042096312 @default.
- W2073640729 hasAuthorship W2073640729A5050441373 @default.
- W2073640729 hasAuthorship W2073640729A5055051085 @default.
- W2073640729 hasAuthorship W2073640729A5057870068 @default.
- W2073640729 hasAuthorship W2073640729A5061331583 @default.
- W2073640729 hasAuthorship W2073640729A5062490222 @default.
- W2073640729 hasAuthorship W2073640729A5074661473 @default.
- W2073640729 hasAuthorship W2073640729A5078275347 @default.
- W2073640729 hasAuthorship W2073640729A5082193608 @default.
- W2073640729 hasConcept C126322002 @default.
- W2073640729 hasConcept C143998085 @default.
- W2073640729 hasConcept C203014093 @default.
- W2073640729 hasConcept C2776694085 @default.
- W2073640729 hasConcept C2776755627 @default.
- W2073640729 hasConcept C2777938653 @default.
- W2073640729 hasConcept C2778461978 @default.
- W2073640729 hasConcept C2779263901 @default.
- W2073640729 hasConcept C2779338263 @default.
- W2073640729 hasConcept C2780653079 @default.
- W2073640729 hasConcept C71924100 @default.
- W2073640729 hasConcept C90924648 @default.
- W2073640729 hasConceptScore W2073640729C126322002 @default.
- W2073640729 hasConceptScore W2073640729C143998085 @default.
- W2073640729 hasConceptScore W2073640729C203014093 @default.
- W2073640729 hasConceptScore W2073640729C2776694085 @default.
- W2073640729 hasConceptScore W2073640729C2776755627 @default.
- W2073640729 hasConceptScore W2073640729C2777938653 @default.
- W2073640729 hasConceptScore W2073640729C2778461978 @default.
- W2073640729 hasConceptScore W2073640729C2779263901 @default.
- W2073640729 hasConceptScore W2073640729C2779338263 @default.